secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001104659-23-064739
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports 19.5-month median OS from DKN-01 combo in gastric cancer; data at ASCO 2023
--------------------------------------------------------------------------------

- Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.
- ORR 73% in mITT population; 86% ORR in PD-L1-low patients; 90% ORR in DKK1-high patients.
- Additional partial response after 22 months of therapy; tumor reductions deepen over time.
- Part C randomized controlled trial enrolling; completion expected late 2023; colorectal data coming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/0001104659-23-064739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/tm2317022d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-064739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer